LAS VEGAS, July 26, 2016 /PRNewswire/ -- Braeburn
Pharmaceuticals announces that healthcare provider training and
certification for Probuphine will take place on July 29, 30 and 31 in Las Vegas. Approved by the Food and Drug
Administration (FDA) on May 26, 2016,
Probuphine is the first implant for the maintenance treatment of
opioid dependence in patients who have sustained clinical stability
on low-to-moderate doses of buprenorphine, specifically 8 mg or
less per day.
Healthcare providers in the Las
Vegas area can register for Probuphine training here or by
calling 1-866-397-8939.
Opioid use disorder is a chronic brain disease and one of the
fastest growing public health epidemics in America. Last year in
Nevada, 545 people died from an
opioid overdose. Research has shown that opioid use disorder is
best treated with a combination of medication and psychosocial
support. The majority of individuals with opioid use disorder
cannot sustain recovery without long-term outpatient medical
treatment.
"Braeburn is committed to making Probuphine available to
patients in the Las Vegas area and
across the country as soon as possible, which is why we're
conducting training sessions so quickly after receiving FDA
approval for Probuphine," said President and CEO Behshad Sheldon, Braeburn Pharmaceuticals. "We
look forward to educating qualified healthcare providers in
Las Vegas on July 29, 30 and 31 on best practices for
insertion and removal of Probuphine, the only treatment for opioid
dependence that delivers medicine for up to six months. To date,
2,236 physicians from all 50 states and Puerto Rico have been certified to provide
Probuphine to their patients."
Probuphine will not be distributed by pharmacies; patients can
only receive the treatment from certified healthcare providers who
have been specially trained to insert the implants just under the
skin of the inside of the upper arm through an in-office
procedure.
This weekend's training sessions for Probuphine in Las Vegas are part of a series of 262 that
Braeburn is conducting across 55 cities this summer.
About Probuphine
Probuphine is the only FDA approved long-acting buprenorphine
treatment for opioid dependence. Probuphine delivers buprenorphine
continuously for six months using Titan Pharmaceuticals' (NASDAQ:
TTNP) ProNeura™ technology. Probuphine is placed under the skin of
the upper arm during an outpatient office procedure and is removed
in a similar manner.
For More Information on Probuphine
Probuphine is now available in all 50 U.S. States. Patients
interested in Probuphine should visit the Probuphine Healthcare
Provider Locator to find a trained and certified provider near
them: www.probuphinerems.com/probuphine-locator.
Probuphine is not distributed by pharmacies. Qualified
healthcare providers can register for Probuphine training at
www.probuphineREMS.com or by calling 1-866-397-8939.
WARNING: IMPLANT MIGRATION, PROTRUSION, EXPULSION and NERVE
DAMAGE ASSOCIATED WITH INSERTION and REMOVAL
Risk Associated with Insertion and Removal
Insertion and removal of PROBUPHINE are associated with the
risk of implant migration, protrusion, expulsion resulting from the
procedure. Rare but serious complications including nerve damage
and migration resulting in embolism and death may result from
improper insertion of drug implants inserted in the upper arm.
Additional complications may include local migration, protrusion
and expulsion. Incomplete insertions or infections may lead to
protrusion or expulsion.
Because of the risks associated with insertion and removal,
PROBUPHINE is available only through a restricted program called
the PROBUPHINE REMS Program. All Healthcare Providers must
successfully complete a live training program on the insertion and
removal procedures and become certified, prior to performing
insertions or prescribing PROBUPHINE implants. Patients must be
monitored to ensure that PROBUPHINE is removed by a healthcare
provider certified to perform insertions.
Please see additional Important Safety Information in the
Package Insert that can be found at probuphine.com or by following
this link
http://probuphinerems.com/wp-content/uploads/2016/02/final-approved-pi.pdf.
About Opioid Use Disorder and Buprenorphine
Opioid use disorder is a chronic brain disease and one of the
fastest growing public health epidemics in America. In the U.S.,
2.5 million people struggle with opioid addiction and, according to
the Centers for Disease Control, 78 people die each day from the
disease. There is a growing body of evidence that opioid addiction
is not a choice or a moral failing, but the result of genetic
predisposition combined with environmental factors. Nonetheless,
individuals struggling with this disease continue to be
stigmatized. Research has also shown that opioid use disorder is
best treated with a combination of medication and psychosocial
support. The majority of individuals with opioid addiction cannot
sustain recovery without long-term outpatient medical
treatment.
Buprenorphine is a partial opioid agonist, which may help
individuals to stop opioid use without experiencing withdrawal
symptoms. Before FDA approval of Probuphine, buprenorphine was only
available in oral form which must be taken daily.
About Braeburn Pharmaceuticals
Braeburn Pharmaceuticals, an Apple Tree Partners company, is a
pharmaceutical company focused on long-acting therapeutic treatment
options that are essential to improving patient outcomes and
facilitating recovery in neurological and psychiatric disorders,
which are often complicated by stigma and present significant
public health challenges. Braeburn's commercial product,
Probuphine® (buprenorphine) implant was approved by the
FDA in May 2016. Braeburn's
investigational product pipeline consists of long-acting
implantable and injectable therapies for serious neurological and
psychiatric disorders, including opioid addiction, pain, and
schizophrenia. Braeburn's pipeline products are at various stages
of clinical development and include CAM2038, weekly and monthly
subcutaneous injection depot formulations of buprenorphine, being
investigated in opioid addiction and pain; a risperidone six-month
implant being investigated in schizophrenia; and a novel molecule,
ATI-9242, is being investigated for treatment of schizophrenia.
More information on Braeburn, can be found at
www.braeburnpharmaceuticals.com.
Media Contacts:
MSLGROUP
Sherry
Feldberg or Rachel Gross
781-684-0770
braeburnpharma@publicisgroupe.net
Coltrin & Associates, Inc.
Caleb Cluff
212-221-1616
caleb_cluff@coltrin.com
Photo
- http://photos.prnewswire.com/prnh/20160725/392706
Logo -
http://photos.prnewswire.com/prnh/20150607/221301LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/braeburn-pharmaceuticals-to-conduct-first-series-of-probuphine-buprenorphine-implant-trainings-in-las-vegas-on-july-29-30-and-31-for-qualified-healthcare-providers-300303559.html
SOURCE Braeburn Pharmaceuticals, Inc.